Research Article
Identification of Risk Factors Associated with Axillary Lymph Node Metastasis for Sentinel Lymph Node-Positive Breast Cancer Patients
Table 3
The relationship between clinicopathological characteristics and N2 disease.
| | Clinicopathological characteristics | Total | Axillary status n (%) | Χ2 | | | (n = 566) | N1 disease | N2 disease | | (%) | n = 465 (82.2) | n = 101 (17.8) |
| | Age | | | | 0.412 | 0.521 | | <50 | 320 (56.5) | 260 (81.2) | 60 (18.8) | | | | ≥50 | 246 (43.5) | 205 (83.3) | 41 (16.7) | | |
| | Pathologic tumor size | | | | 1.906 | 0.167 | | T1 ≤2 cm | 293 (51.8) | 247 (84.3) | 46 (15.7) | | | | T2 ≤5 cm | 273 (48.2) | 218 (79.9) | 55 (20.1) | | |
| | Tumor type | | | | 0.472 | 0.821 | | Ductal | 530 (93.6) | 435 (82.1) | 95 (17.9) | | | | Lobular | 11 (1.9) | 10 (90.9) | 1 (9.1) | | | | Other | 25 (4.4) | 20 (80.0) | 5 (20.0) | | |
| | Nuclear grade | | | | 3.251 | 0.197 | | I | 24 (4.2) | 21 (87.5) | 3 (12.5) | | | | II | 256 (45.2) | 214 (83.6) | 42 (16.4) | | | | III | 250 (44.2) | 195 (78.0) | 55 (22.0) | | | | N/A | 36 (6.4) | 35 (97.2) | 1 (2.8) | | |
| | LVI | | | | 5.678 | 0.017 | | Present | 237 (41.9) | 184 (77.6) | 53 (22.4) | | | | Absent | 329 (58.1) | 281 (85.4) | 48 (14.6) | | |
| | Multifocality | | | | 0.160 | 0.689 | | Multifocal/yes | 78 (13.8) | 64 (82.1) | 14 (17.9) | | | | Unifocal/no | 471 (83.2) | 395 (83.9) | 76 (16.1) | | | | N/A | 17 (3.0) | 6 (35.3) | 11 (64.7) | | |
| | Surgery | | | | 1.348 | 0.246 | | Conservative | 293 (51.8) | 246 (84.0) | 47 (16.0) | | | | Mastectomy | 273 (48.2) | 219 (80.2) | 54 (19.8) | | |
| | ER receptor status | | | | 1.035 | 0.309 | | Positive | 507 (89.6) | 419 (82.6) | 88 (17.4) | | | | Negative | 57 (10.1) | 44 (77.2) | 13 (22.8) | | | | N/A | 2 (0.4) | 2 (100) | 0 (0) | | |
| | PR receptor status | | | | 0.055 | 0.814 | | Positive | 457 (80.7) | 376 (82.3) | 81 (17.7) | | | | Negative | 107 (18.9) | 87 (81.3) | 20 (18.7) | | | | N/A | 2 (0.4) | 2 (100) | 0 (0) | | |
| | HER2 | | | | 7.425 | 0.006 | | Positive | 117 (20.7) | 86 (73.5) | 31 (26.5) | | | | Negative | 406 (71.7) | 343 (84.5) | 63 (15.5) | | | | N/A | 43 (7.6) | 36 (83.7) | 7 (16.3) | | |
| | Ki-67 status | | | | 0.687 | 0.407 | | <14% | 82 (14.5) | 71 (86.6) | 11 (13.4) | | | | ≥14% | 450 (79.5) | 373 (82.9) | 77 (17.1) | | | | N/A | 34 (6.0) | 21 (61.8) | 13 (38.2) | | |
| | Number of positive SLNs | | | | 42.388 | <0.001 | | 1 | 420 (74.2) | 371 (88.3) | 49 (11.7) | | | | 2 | 146 (25.8) | 94 (64.4) | 52 (35.6) | | |
| | SLN metastasis ratio | | | | 20.723 | <0.001 | | <50% | 238 (42.0) | 216 (90.8) | 22 (9.2) | | | | ≥50% | 328 (58.0) | 249 (75.9) | 79 (24.1) | | |
| | Size of SLN metastasis | | | | 2.663 | 0.138 | | Micrometastasis | 12 (2.1) | 12 (100.0) | 0 (0) | | | | Macrometastasis | 554 (97.9) | 453 (81.8) | 101 (18.2) | | |
| | IHC-based subtype | | | | 9.189 | 0.050 | | Luminal A | 62 (11.0) | 54 (87.1) | 8 (12.9) | | | | Luminal/HER2(−) | 300 (53) | 252 (84) | 48 (16) | | | | Luminal/HER2(+) | 91(16) | 69 (75.8) | 22(24.2) | | | | HER2(+) | 22 (3.9) | 14 (63.6) | 8 (36.4) | | | | Triple-negative | 19 (3.4) | 17 (89.5) | 2 (10.5) | | | | N/A | 72 (12.7) | 59 (81.9) | 13 (18.1) | | |
|
|
SLN, sentinel lymph node; LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.
|
